{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-proliferative", "EGFR inhibitors", "MD simulations", "apoptosis", "thieno[2,3-d]pyrimidines"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37288786", "DateCompleted": {"Year": "2023", "Month": "06", "Day": "09"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "12"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["2220579", "10.1080/14756366.2023.2220579"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "38", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-<i>d</i>]pyrimidine derivatives as new EGFR inhibitors.", "Pagination": {"StartPage": "2220579", "MedlinePgn": "2220579"}, "Abstract": {"AbstractText": ["A group of EGFR inhibitors derived from thieno[2,3-<i>d</i>]pyrimidine nucleus was designed, synthesised, and examined as anti-proliferative lead compounds. MCF-7 and A549 cell lines were inhibited by <b>5b</b>, the most active member. It had inhibitory partialities of 37.19 and 204.10\u2009nM against EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>, respectively. Compound <b>5b</b> was 2.5 times safer against the WI-38 normal cell lines than erlotinib. Also, it demonstrated considerable potentialities for both early and late apoptosis induction in A549. Simultaneously, <b>5b</b> arrested A549's growth at G1 and G2/M phases. Harmoniously, <b>5b</b> upregulated the BAX and downregulated the Bcl-2 genes by 3-fold and increased the BAX/Bcl-2 ratio by 8.3-fold comparing the untreated A549 cells. Molecular docking against EGFR<sup>WT</sup> and EGFR<sup>T790M</sup> indicated the correct binding modes. Furthermore, MD simulations confirmed the precise binding of <b>5b</b> against the EGFR protein over 100\u2009ns. Finally, various computational ADMET studies were carried out and indicated high degrees of drug-likeness and safety."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt."}], "LastName": "Sobh", "ForeName": "Eman A", "Initials": "EA"}, {"Identifier": ["0000-0002-2016-0728"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Dahab", "ForeName": "Mohammed A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "bcl-2-Associated X Protein"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "bcl-2-Associated X Protein"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["chemistry"], "DescriptorName": "Pyrimidines"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "The authors report no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249.", "ArticleIdList": ["33538338"]}, {"Citation": "WHO. Cancer, Overview . [accessed 2022.  Oct 1]. https://www.who.int/health-topics/cancer#tab=tab_1."}, {"Citation": "Badran MM, Abouzid KM, Hussein MHM.. Synthesis of certain substituted quinoxalines as antimicrobial agents (part II). Arch Pharm Res. 2003;26(2):107\u2013113.", "ArticleIdList": ["12643584"]}, {"Citation": "WHO. Cancer, Key facts . [accessed 2023 Mar 1]. https://www.who.int/news-room/fact-sheets/detail/cancer."}, {"Citation": "Chabner BA, Roberts TG.. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65\u201372.", "ArticleIdList": ["15630416"]}, {"Citation": "Krauss G, Sch\u00f6nbrunner N, Cooper J.. Biochemistry of signal transduction and regulation. Weinheim (Germany): Wiley Online Library; 2003. Vol. 3."}, {"Citation": "Nguyen K-SH, Kobayashi S, Costa DB.. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281\u2013289.", "ArticleIdList": ["PMC2758558", "19632948"]}, {"Citation": "Grant S. Therapeutic protein kinase inhibitors. Cell Mol Life Sci. 2009;66(7):1163\u20131177.", "ArticleIdList": ["19011754"]}, {"Citation": "Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS, et al. . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2\u201316.", "ArticleIdList": ["16377102"]}, {"Citation": "Huang S-M, Harari PM.. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17(3):259\u2013269.", "ArticleIdList": ["10665478"]}, {"Citation": "Nicholson RI, Gee JMW, Harper ME.. egfR and cancer prognosis. Eur J Cancer. 2001;37:9\u201315.", "ArticleIdList": ["11597399"]}, {"Citation": "Zhang H-Q, Gong F-H, Ye J-Q, Zhang C, Yue X-H, Li C-G, Xu Y-G, Sun L-P.. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. Eur J Med Chem. 2017;125:245\u2013254.", "ArticleIdList": ["27688180"]}, {"Citation": "Song Z, Huang S, Yu H, Jiang Y, Wang C, Meng Q, Shu X, Sun H, Liu K, Li Y, et al. . Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem. 2017;133:329\u2013339.", "ArticleIdList": ["28395219"]}, {"Citation": "Zhang Y, Chen L, Xu H, Li X, Zhao L, Wang W, Li B, Zhang X.. 6, 7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur J Med Chem. 2018;147:77\u201389.", "ArticleIdList": ["29421573"]}, {"Citation": "Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003;12(8):1395\u20131401.", "ArticleIdList": ["12882624"]}, {"Citation": "Ou S-HI. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012;83(3):407\u2013421.", "ArticleIdList": ["22257651"]}, {"Citation": "Walter AO, Sjin RTT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, et al. . Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013;3(12):1404\u20131415.", "ArticleIdList": ["PMC4048995", "24065731"]}, {"Citation": "Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, et al. . Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non\u2013small-cell lung cancer. J Clin Oncol. 2010;28(18):3076\u20133083.", "ArticleIdList": ["20479403"]}, {"Citation": "Kim Y, Ko J, Cui ZYun, Abolhoda A, Ahn JS, Ou S-H, Ahn M-J, Park K.. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784\u2013791.", "ArticleIdList": ["22228822"]}, {"Citation": "Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS.. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol. 2014;9(6):1230\u20131241.", "ArticleIdList": ["PMC4068218", "24730530"]}, {"Citation": "Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U, Traxler P.. Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des. 1995;9(6):465\u2013472.", "ArticleIdList": ["8789188"]}, {"Citation": "Gandin V, Ferrarese A, Dalla Via M, Marzano C, Chilin A, Marzaro G.. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci Rep. 2015;5:16750.", "ArticleIdList": ["PMC4645160", "26568452"]}, {"Citation": "Liu Y, Gray NS.. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358\u2013364.", "ArticleIdList": ["16783341"]}, {"Citation": "Elrazaz EZ, Serya RAT, Ismail NSM, Abou El Ella DA, Abouzid KAM.. Thieno [2, 3-d] pyrimidine based derivatives as kinase inhibitors and anticancer agents. Future J Pharm Sci. 2015;1(2):33\u201341."}, {"Citation": "Yang C-R, Peng B, Cao S-L, Ren T-T, Jiang W, Wang F-C, Li Y-S, Wang G, Li Z, Xu S, et al. . Synthesis, cytotoxic evaluation and target identification of thieno [2, 3-d] pyrimidine derivatives with a dithiocarbamate side chain at C2 position. Eur J Med Chem. 2018;154:324\u2013340.", "ArticleIdList": ["29843103"]}, {"Citation": "Rashad A, Ali M.. Synthesis and antiviral screening of some thieno [2, 3-d] pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids. 2006;25(1):17\u201328.", "ArticleIdList": ["16440982"]}, {"Citation": "Kotaiah Y, Harikrishna N, Nagaraju K, Venkata Rao C.. Synthesis and antioxidant activity of 1, 3, 4-oxadiazole tagged thieno [2, 3-d] pyrimidine derivatives. Eur J Med Chem. 2012;58:340\u2013345.", "ArticleIdList": ["23149297"]}, {"Citation": "Vega S, Alonso J, Diaz JA, Junquera F, Perez C, Darias V, Bravo L, Abdallah S.. Thiophene isosteres: synthesis and biological evaluation of 3-substituted derivatives of 4-phenyl-2-thioxo-benzo [4, 5] thieno [2, 3-d] pyrimidine. Eur J Med Chem . 1991;26(3):323\u2013329."}, {"Citation": "El-Gazzar A-R, Hussein H, Hafez H.. Synthesis and biological evaluation of thieno [2, 3-d] pyrimidine derivatives for anti-inflammatory, analgesic and ulcerogenic activity. Acta Pharm. 2007;57(4):395\u2013411.", "ArticleIdList": ["18165185"]}, {"Citation": "Vlasov SV, Osolodchenko TP, Kovalenko SM, Chernykh VP.. Synthesis and the antimicrobial activity of 1-alkyl-5-methyl-3-phenyl-6-(5-phenyl-1, 3, 4-oxadiazol-2-yl) thieno [2, 3-d] pyrimidine-2, 4 (1H, 3H)-diones. J Org Pharm Chem. 2015;13(1(49)):20\u201324."}, {"Citation": "Ali EMH, Abdel-Maksoud MS, Oh C-H. [2, 3-d] pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. Bioorg Med Chem. 2019;27(7):1159\u20131194.", "ArticleIdList": ["30826188"]}, {"Citation": "Bugge S, Kaspersen SJ, Larsen S, Nonstad U, Bj\u00f8rk\u00f8y G, Sundby E, Hoff BH.. Structure\u2013activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. Eur J Med Chem. 2014;75:354\u2013374.", "ArticleIdList": ["24556149"]}, {"Citation": "Gaber AA, Bayoumi AH, El-Morsy AM, Sherbiny FF, Mehany ABM, Eissa IH.. Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg Chem. 2018;80:375\u2013395.", "ArticleIdList": ["29986185"]}, {"Citation": "Elmetwally SA, Saied KF, Eissa IH, Elkaeed EB.. Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem. 2019;88:102944.", "ArticleIdList": ["31051400"]}, {"Citation": "Nasser AA, Eissa IH, Oun MR, El-Zahabi MA, Taghour MS, Belal A, Saleh AM, Mehany ABM, Luesch H, Mostafa AE, et al. . Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org Biomol Chem. 2020;18(38):7608\u20137634.", "ArticleIdList": ["32959865"]}, {"Citation": "Zhao Z, Xie L, Bourne PE.. Structural insights into characterizing binding sites in epidermal growth factor receptor kinase mutants. J Chem Inf Model. 2019;59(1):453\u2013462.", "ArticleIdList": ["PMC6441332", "30582689"]}, {"Citation": "Kandeel MM, Mounir AA, Refaat HM, Kassab AE.. Synthesis of thieno [2, 3-d] pyrimidines, thieno [2, 3-d] triazinones and thieno [2, 3-e] diazepinones of anticipated anti-cancer activity. J Chem Res. 2012;36(2):105\u2013110."}, {"Citation": "Tormyshev V, Trukhin D, Rogozhnikova O, Mikhalina T, Troitskaya T, Flinn A.. Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes. Synlett. 2006;2006(16):2559\u20132564."}, {"Citation": "El\u2010Adl K, Ibrahim M\u2010K, Khedr F, Abulkhair HS, Eissa IH.. N\u2010Substituted\u20104\u2010phenylphthalazin\u20101\u2010amine\u2010derived VEGFR\u20102 inhibitors: design, synthesis, molecular docking, and anticancer evaluation studies. Arch Pharm. 2021;354(3):2000219.", "ArticleIdList": ["33197080"]}, {"Citation": "Abdelhaleem EF, Abdelhameid MK, Kassab AE, Kandeel MM.. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Eur J Med Chem. 2018;143:1807\u20131825.", "ArticleIdList": ["29133058"]}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55\u201363.", "ArticleIdList": ["6606682"]}, {"Citation": "Denizot F, Lang R.. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271\u2013277.", "ArticleIdList": ["3486233"]}, {"Citation": "Thabrew MI, Hughes RD, Mcfarlane IG.. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol. 1997;49(11):1132\u20131135.", "ArticleIdList": ["9401951"]}, {"Citation": "Li P, Zhang Q, Torossian A, Li Z-b, Xu W-c, Lu B, Fu S.. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):e391\u2013e397.", "ArticleIdList": ["22414288"]}, {"Citation": "Huether A, H\u00f6pfner M, Baradari V, Schuppan D, Scher\u00fcbl H.. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70(11):1568\u20131578.", "ArticleIdList": ["16226226"]}, {"Citation": "Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG.. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non\u2013small cell lung cancer cells. Mol Cancer Ther. 2006;5(5):1154\u20131165.", "ArticleIdList": ["16731747"]}, {"Citation": "Jia Y, Quinn CM, Gagnon AI, Talanian R.. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem. 2006;356(2):273\u2013281.", "ArticleIdList": ["16814737"]}, {"Citation": "Pietenpol J, Stewart Z.. Cell cycle checkpoint signaling:: cell cycle arrest versus apoptosis. Toxicology. 2002;181-182:475\u2013481.", "ArticleIdList": ["12505356"]}, {"Citation": "Park JH, Liu Y, Lemmon MA, Radhakrishnan R.. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J. 2012;448(3):417\u2013423.", "ArticleIdList": ["PMC3507260", "23101586"]}, {"Citation": "Sogabe S, Kawakita Y, Igaki S, Iwata H, Miki H, Cary DR, Takagi T, Takagi S, Ohta Y, Ishikawa T, et al. . Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med Chem Lett. 2013;4(2):201\u2013205.", "ArticleIdList": ["PMC4027575", "24900643"]}, {"Citation": "Ferreira LL, Andricopulo A.. ADMET modeling approaches in drug discovery. Drug Discov Today. 2019;24(5):1157\u20131165.", "ArticleIdList": ["30890362"]}, {"Citation": "Dearden JC. In silico prediction of drug toxicity. J Comput Aided Mol Des. 2003;17(2-4):119\u2013127.", "ArticleIdList": ["13677480"]}, {"Citation": "Kruhlak NL, Benz RD, Zhou H, Colatsky TJ. (Q) SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther. 2012;91(3):529\u2013534.", "ArticleIdList": ["22258468"]}, {"Citation": "Golub AG, Bdzhola VG, Briukhovetska NV, Balanda AO, Kukharenko OP, Kotey IM, Ostrynska OV, Yarmoluk SM.. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem. 2011;46(3):870\u2013876.", "ArticleIdList": ["21276643"]}, {"Citation": "Abbas SE, Abdel Gawad NM, George RF, Akar YA.. Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives. Eur J Med Chem. 2013;65:195\u2013204.", "ArticleIdList": ["23708013"]}, {"Citation": "Al-Rashood ST, Hamed AR, Hassan GS, Alkahtani HM, Almehizia AA, Alharbi A, Al-Sanea MM, Eldehna WM.. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J Enzyme Inhib Med Chem. 2020;35(1):831\u2013839.", "ArticleIdList": ["PMC7144320", "32208781"]}, {"Citation": "Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, et al. . New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem. 2022;37(1):403\u2013416.", "ArticleIdList": ["PMC8725875", "34961427"]}, {"Citation": "Wang J, Lenardo MJ.. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci. 2000;113(5):753\u2013757.", "ArticleIdList": ["10671365"]}, {"Citation": "Eldehna WM, Hassan GS, Al-Rashood ST, Al-Warhi T, Altyar AE, Alkahtani HM, Almehizia AA, Abdel-Aziz HA.. Synthesis and in\u00a0vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem. 2019;34(1):322\u2013332.", "ArticleIdList": ["PMC6366416", "30722708"]}, {"Citation": "Lo KK-W, Lee TK-M, Lau JS-Y, Poon W-L, Cheng S-H.. Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg Chem. 2008;47(1):200\u2013208.", "ArticleIdList": ["18067284"]}, {"Citation": "Sabt A, Abdelhafez OM, El-Haggar RS, Madkour HMF, Eldehna WM, El-Khrisy EE-DAM, Abdel-Rahman MA, Rashed LA.. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in\u00a0vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem. 2018;33(1):1095\u20131107.", "ArticleIdList": ["PMC6022226", "29944015"]}, {"Citation": "Balah A, Ezzat O, Akool E-S.. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-\u03b2/Smad signaling pathway in rat liver. Int Immunopharmacol. 2018;65:493\u2013502.", "ArticleIdList": ["30391882"]}, {"Citation": "Aborehab NM, Elnagar MR, Waly NE.. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF\u20107 human breast cancer cell line. J Biochem Mol Toxicol. 2021;35(2):e22638.", "ArticleIdList": ["33002289"]}, {"Citation": "Elnagar MR, Walls AB, Helal GK, Hamada FM, Thomsen MS, Jensen AA.. Functional characterization of \u03b17 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Eur J Pharmacol. 2018;826:106\u2013113.", "ArticleIdList": ["29501870"]}, {"Citation": "Elkaeed EB, Eissa IH, Elkady H, Abdelalim A, Alqaisi AM, Alsfouk AA, Elwan A, Metwaly AM.. A multistage in silico study of natural potential inhibitors targeting SARS-CoV-2 main protease. Int J Mol Sci. 2022;23(15):8407.", "ArticleIdList": ["PMC9369012", "35955547"]}, {"Citation": "Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML, El Hassab MA, Abou-Seri SM, Metwaly AM.. Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. Int J Mol Sci. 2022;23(13):6912.", "ArticleIdList": ["PMC9266348", "35805916"]}, {"Citation": "Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk BA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH.. Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: in\u00a0vitro anticancer and VEGFR-2 inhibitory effects. Molecules. 2022;27(14):4606.", "ArticleIdList": ["PMC9317904", "35889478"]}, {"Citation": "Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, Eissa IH, et al. . Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem. 2022;37(1):1903\u20131917.", "ArticleIdList": ["PMC9272924", "35801403"]}, {"Citation": "Yousef RG, Sakr HM, Eissa IH, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, El-Adl K, et al. . New quinoxaline-2 (1\u2009H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J Chem. 2021;45(36):16949\u201316964."}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "6", "Day": "9", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "6", "Day": "8", "Hour": "13", "Minute": "8"}, {"Year": "2023", "Month": "6", "Day": "8", "Hour": "7", "Minute": "24"}, {"Year": "2023", "Month": "6", "Day": "8"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37288786", "PMC10251802", "10.1080/14756366.2023.2220579"]}}], "PubmedBookArticle": []}